TerminatedPhase 1NCT00023634
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Robert B. Montgomery, MDVA Puget Sound Health Care System
- Intervention
- KLH(biological)
- Enrollment
- 14 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2001 – 2008
Study locations (13)
- Bay Regional Medical Center, Bay City, Michigan, United States
- Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States
- St. Joseph Hospital Community Cancer Center, Bellingham, Washington, United States
- Olympic Hematology and Oncology, Bremerton, Washington, United States
- Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
- Harborview Medical Center, Seattle, Washington, United States
- Group Health Central Hospital, Seattle, Washington, United States
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States
- University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States
- North Puget Oncology at United General Hospital, Sedro-Woolley, Washington, United States
- Cancer Care Northwest - Spokane South, Spokane, Washington, United States
- Wenatchee Valley Clinic, Wenatchee, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00023634 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →